2024
C-reactive protein orchestrates acute allograft rejection in vascularized composite allotransplantation via selective activation of monocyte subsets
Kiefer J, Zeller J, Schneider L, Thomé J, McFadyen J, Hoerbrand I, Lang F, Deiss E, Bogner B, Schaefer A, Chevalier N, Horner V, Kreuzaler S, Kneser U, Kauke-Navarro M, Braig D, Woollard K, Pomahac B, Peter K, Eisenhardt S. C-reactive protein orchestrates acute allograft rejection in vascularized composite allotransplantation via selective activation of monocyte subsets. Journal Of Advanced Research 2024, 72: 401-420. PMID: 38992424, PMCID: PMC12147648, DOI: 10.1016/j.jare.2024.07.007.Peer-Reviewed Original ResearchAcute allograft rejectionC-reactive proteinVascularized Composite AllotransplantationAllograft rejectionAcute rejectionAllograft survivalGraft rejectionAttenuate acute allograft rejectionPreventing acute allograft rejectionImmune responseLong-term allograft survivalFacial Vascularized Composite AllotransplantationClinical allograft rejectionReduced allograft survivalChronic allograft rejectionIntravital imagingNon-classical monocytesMarkers of inflammationAcute-phase reactantsImmune-inflammatory reactionPro-inflammatory propertiesMononuclear phagocyte systemAcute-phase responseGraft infiltrationInnate immune response
2011
Report on the Safety of Velaglucerase Alfa Enzyme Replacement Therapy in Patients with Type 1 Gaucher Disease and the Transition From Clinic to Home Infusions During Treatment Protocol HGT-GCB-058
Pastores G, Rosenbloom B, Weinreb N, Goker-Alpan O, Mardach R, Lipson M, Ibrahim J, Cohn G, Zahrieh D, Mistry P. Report on the Safety of Velaglucerase Alfa Enzyme Replacement Therapy in Patients with Type 1 Gaucher Disease and the Transition From Clinic to Home Infusions During Treatment Protocol HGT-GCB-058. Blood 2011, 118: 1101. DOI: 10.1182/blood.v118.21.1101.1101.Peer-Reviewed Original ResearchType 1 Gaucher's diseaseEnzyme replacement therapyTreatment-naïve patientsAdverse eventsSwitch patientsHome infusionHome therapyVelaglucerase alfaGaucher diseaseSpeakers bureauSerious AEsReplacement therapyVelaglucerase alfa enzyme replacement therapyClinical sitesInfusion-related adverse eventsCommon adverse eventsMost adverse eventsVelaglucerase alfa treatmentSerious adverse eventsSevere adverse eventsBone marrow pathologyAccumulation of glucosylceramideMononuclear phagocyte systemAdvisory CommitteeImiglucerase treatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply